Medications and the Nutrients They Drain
2026-11-10Same post, two depths. Switch any time; the research version has the enzyme names, lab markers, and doses. Written from a research and education perspective: a model of what may be going on and what the published literature suggests would address it if the model is right, not medical advice or a treatment plan.
Medications are the single most common cause of nutrient shortfalls I come across, and almost nobody is told at the pharmacy counter. A drug that lowers stomach acid lowers B12, iron, magnesium, and zinc. A drug that lowers blood sugar lowers B12. A drug that lowers cholesterol lowers CoQ10. The drug is often doing its job well. The deficiency it creates is a separate problem, it builds slowly, and it is usually blamed on something else.
This page is a lookup table: find your medication, see what it drains, and see what the research suggests for watching and replacing it. It is not a reason to stop a medication. It is a reason to test and, with your provider, to replace what is being lost.
How to use it: the "what to watch" column is the lab from the Lab Guide here; the "what the research suggests" column is the nutrient and form from the Nutrient Guide here. Timing notes tell you when a supplement has to be taken apart from the drug so neither blocks the other.
Stomach acid and digestion
| Medication | Drains | Why | What to watch | What the research suggests |
|---|---|---|---|---|
| Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole, lansoprazole) | B12, magnesium, iron, zinc, calcium, vitamin C, possibly beta-carotene | Acid is needed to release B12 from food, to keep iron soluble, and to run the magnesium channel in the gut | MMA, RBC magnesium, ferritin and saturation, plasma zinc; yearly | Sublingual hydroxo/adenosyl B12; magnesium glycinate; iron only by ferritin; zinc balanced with copper; and a real conversation about whether the PPI is still needed (see the stomach acid post here) |
| H2 blockers (famotidine) | B12, iron, zinc (milder than PPIs) | Same mechanism, less complete | MMA, ferritin | As above, lower priority |
| Antacids (calcium carbonate, aluminum, magnesium hydroxide) | Iron, folate, phosphate (aluminum); may raise magnesium | Bind minerals in the gut | Ferritin if daily use | Take iron and other minerals two hours apart |
| Bile acid sequestrants (cholestyramine, colestipol) | Vitamins A, D, E, K, folate, iron, zinc, magnesium | Bind fat and the fat-soluble vitamins with it | 25-OH-D, INR or ucOC, retinol | Fat-soluble vitamins taken 4 hours apart from the drug |
| Orlistat | Vitamins A, D, E, K, beta-carotene | Blocks fat absorption | 25-OH-D | Fat-soluble multivitamin at bedtime, apart from the drug |
Blood sugar
| Medication | Drains | Why | What to watch | What the research suggests |
|---|---|---|---|---|
| Metformin | B12 (in up to 30 percent of long-term users), folate; raises homocysteine | Blocks the calcium-dependent step of B12 absorption in the ileum | MMA and holoTC yearly; homocysteine | Hydroxo/adenosyl B12 1,000 mcg; the neuropathy blamed on diabetes is sometimes the B12 |
| Sulfonylureas, SGLT2 inhibitors | Minor; SGLT2 drugs raise magnesium and lose some B vitamins in urine | RBC magnesium | Usually nothing specific | |
| Insulin | Magnesium, potassium (shifts into cells) | Insulin drives both into cells | RBC magnesium | Magnesium if low |
Cholesterol and heart
| Medication | Drains | Why | What to watch | What the research suggests |
|---|---|---|---|---|
| Statins (atorvastatin, rosuvastatin, simvastatin) | CoQ10, vitamin K2 (MK-4), possibly vitamin D and selenium; lower omega-3 slightly | Block the enzyme at the branch point that also makes CoQ10 and the carrier for K2 | Muscle symptoms, CK if aching; omega-3 index | Ubiquinol 100 to 200 mg with a meal (the muscle-ache evidence is mixed but the depletion is not); K2 MK-7 |
| Loop diuretics (furosemide, torsemide) | Thiamine, magnesium, potassium, zinc, calcium, B6 | Washed out in urine | Whole-blood TPP, RBC magnesium, potassium | Benfotiamine or thiamine; magnesium; potassium by prescriber |
| Thiazides (hydrochlorothiazide, chlorthalidone) | Magnesium, potassium, zinc, sodium; raise calcium | Renal loss | RBC magnesium, potassium, zinc | Magnesium; zinc with copper |
| ACE inhibitors and ARBs | Zinc; raise potassium | Zinc lost in urine with ACE inhibitors | Zinc, potassium | Zinc balanced with copper; no potassium supplements without prescriber |
| Beta blockers | CoQ10, melatonin | Block CoQ10-dependent enzymes; suppress nighttime melatonin release | Sleep quality | Ubiquinol; melatonin 0.5 to 1 mg if sleep is affected |
| Digoxin | Magnesium, thiamine, calcium | Renal loss; the magnesium matters for toxicity | RBC magnesium | Magnesium (low magnesium makes digoxin dangerous) |
| Hydralazine | B6 | Binds the active form | Plasma P5P | P5P 25 to 50 mg |
| Warfarin | Vitamin K (by design) | Blocks K recycling | INR | Keep intake steady, do not start or stop K-containing supplements without the prescriber |
| Aspirin, long term | Vitamin C, folate, iron (through bleeding) | Gut lining, excretion | Ferritin | Vitamin C; iron by ferritin |
Hormones
| Medication | Drains | Why | What to watch | What the research suggests |
|---|---|---|---|---|
| Combined oral contraceptives | B6, folate, B12, B2, vitamin C, zinc, magnesium, selenium; raise copper, iron, and vitamin A | Estrogen raises copper-binding protein and shifts B6 metabolism | Plasma P5P, RBC folate, zinc and copper together, homocysteine | P5P; folinic acid or methylfolate; magnesium; zinc (ratio matters: copper is already high on the pill) |
| Hormone replacement (oral estrogen) | Similar to the pill; raises copper and SHBG | Same | Copper and zinc | As above |
| Corticosteroids (prednisone, inhaled and nasal at high doses) | Calcium, vitamin D, potassium, magnesium, zinc, vitamin C, chromium; protein (muscle) | Raise excretion, block absorption, break down tissue | 25-OH-D, bone density on long courses, potassium | Vitamin D with K2 and magnesium; protein; calcium from food |
| Levothyroxine | None directly, but absorption is blocked by calcium, iron, soy, coffee, and PPIs | TSH, free T3 | Take on an empty stomach, 4 hours apart from iron and calcium | |
| Spironolactone | Raises potassium; may lower zinc | Potassium | No potassium supplements |
Antibiotics and antimicrobials
| Medication | Drains | Why | What to watch | What the research suggests |
|---|---|---|---|---|
| Any broad-spectrum antibiotic | Vitamin K2, biotin, B vitamins made by gut bacteria; disrupts the microbiome | Kills the producers | None routinely | A course of probiotics after, not during; K2 and B complex if a long course |
| Tetracyclines (doxycycline, minocycline) | Calcium, magnesium, iron, zinc (and the drug binds them) | Chelation in the gut | Take minerals 2 to 3 hours apart from the drug | |
| Fluoroquinolones (ciprofloxacin, levofloxacin) | Magnesium, iron, zinc, copper; damage mitochondria and collagen | Chelate the metals the collagen enzymes need; mitochondrial toxicity | Tendon pain, fatigue, nerve symptoms | Avoid in hypermobile people unless no alternative; magnesium during and after; NAC and vitamin E plus selenium have early prevention data; no iron or copper during the acute phase |
| Trimethoprim-sulfamethoxazole (Bactrim) | Folate | Blocks the folate enzyme | RBC folate if long term | Folinic acid |
| Isoniazid | B6, B3 | Binds B6; blocks niacin synthesis | Neuropathy | P5P is standard with it |
| Metronidazole | Possibly B vitamins, taste changes from zinc | Zinc if taste is affected | ||
| Antifungals (fluconazole, ketoconazole) | Ketoconazole lowers vitamin D activation and cortisol | 25-OH-D | Vitamin D |
Pain, mood, and nerves
| Medication | Drains | Why | What to watch | What the research suggests |
|---|---|---|---|---|
| NSAIDs (ibuprofen, naproxen), long term | Iron (bleeding), folate, vitamin C; damage the gut lining | Mucosal injury | Ferritin, stool calprotectin | Iron by ferritin; zinc-carnosine and glutamine for the lining |
| Acetaminophen, regular use | Glutathione | Consumed in clearing it | GGT | NAC and glycine; never combine with alcohol |
| Opioids | Nothing directly; constipation blocks every mineral's exit route and raises recycled estrogen | Bowel function | Magnesium citrate, fiber | |
| SSRIs and SNRIs | Sodium (hyponatremia in older adults), possibly folate and B12 utilization; folate status predicts response | Sodium in older adults | Methylfolate has trial data as an add-on when folate is low | |
| Tricyclics | B2, CoQ10 | B2, ubiquinol | ||
| Anticonvulsants (valproate, carbamazepine, phenytoin, phenobarbital) | Folate, vitamin D, biotin, carnitine (valproate), vitamin K, B12, calcium | Induce liver enzymes that clear vitamins; valproate blocks carnitine | RBC folate, 25-OH-D, carnitine (valproate), bone density | Folinic acid (not folic acid; some anticonvulsants interact), vitamin D with K2, biotin, L-carnitine with valproate |
| Gabapentin, pregabalin | Minor | |||
| Lithium | Raises calcium, lowers thyroid function and sodium handling | Calcium, thyroid, sodium | Prescriber-managed | |
| Antipsychotics | Raise insulin resistance; may lower B2 and CoQ10 | Fasting insulin, lipids | Metabolic monitoring | |
| Nitrous oxide (dental, surgical, recreational) | B12, permanently inactivates the enzyme | Oxidizes the cobalt in B12 | MMA, homocysteine after any exposure if symptoms | Hydroxocobalamin before and after planned exposure; this is the one that causes spinal cord damage in B12-marginal people |
Other common ones
| Medication | Drains | Why | What to watch | What the research suggests |
|---|---|---|---|---|
| Methotrexate | Folate (by design), B12 utilization | Blocks the folate enzyme | RBC folate, CBC | Folinic acid on the days the prescriber sets; never on the methotrexate day without instruction |
| Sulfasalazine | Folate | Blocks absorption and the enzyme | RBC folate | Folinic acid |
| Colchicine | B12 | Damages the absorbing cells | MMA | B12 |
| Allopurinol | None major | |||
| Bisphosphonates | None, but need calcium and D to work | 25-OH-D | Vitamin D with K2 and magnesium | |
| Chemotherapy (platinum, taxanes, 5-FU) | Magnesium (platinum), B vitamins, glutathione, many others | Renal loss, mucosal damage | RBC magnesium | Oncology-directed; never add antioxidants during active treatment without the oncologist |
| Alcohol (a drug, in this table on merit) | Thiamine, folate, B6, B12, magnesium, zinc, vitamin A, vitamin C, selenium, glutathione | Blocks absorption, raises loss, consumes glutathione, poisons the gut lining | Whole-blood TPP, RBC folate, RBC magnesium, GGT | Thiamine first (before any glucose), then the rest; less alcohol |
| Caffeine, heavy use | Calcium, magnesium, iron (if with meals), B vitamins through urine | Diuretic; tannins bind iron | Coffee apart from iron-containing meals | |
| Smoking and nicotine | Vitamin C (needs about 35 mg more a day), folate, B12, vitamin E, zinc, selenium | Oxidative load | Plasma ascorbate | Vitamin C; stopping |
The patterns worth noticing
Three drugs, one deficiency. A PPI plus metformin plus a vegetarian diet is a B12 deficiency waiting to be found. A thiazide plus a PPI plus daily coffee is a magnesium deficiency. The pill plus a statin plus a low-fat diet is a CoQ10, B6, and zinc picture with copper running high.
The deficiency gets blamed on the disease. Metformin's neuropathy is often B12. Statin myalgia is often CoQ10. The fatigue on a PPI is often magnesium and B12. Prednisone's weakness is partly protein and potassium. Anticonvulsant bone loss is vitamin D and K. Testing separates the drug effect from the disease effect, and the fix for the deficiency does not require stopping the drug.
Timing solves half of it. Levothyroxine, tetracyclines, fluoroquinolones, and bisphosphonates all need a gap of 2 to 4 hours from iron, calcium, magnesium, and zinc. Fat-soluble vitamins need a gap from sequestrants and orlistat. Most of the rest can be taken together.
Do not stop a drug because of this page. Every one of these is a conversation with the prescriber. The point is to test what the drug is known to drain, replace it in the right form, and recheck.
Educational content written from a research perspective, not medical advice. I am a PhD scientist, not a physician, and I do not diagnose, treat, cure, or prevent disease. Medication decisions belong with your prescriber; several supplements here interact with the drugs they are listed next to (vitamin K with warfarin, potassium with ACE inhibitors and spironolactone, folate with methotrexate, antioxidants with chemotherapy) and must be discussed first.
Framing
Drug-induced nutrient depletion is well documented for individual agents and almost never assessed in practice, partly because the deficiency develops over months to years, partly because its presentation is attributed to the underlying disease, and partly because routine panels do not include the markers that would detect it. This page is a reference by drug class: the nutrients affected, the mechanism, the monitoring assay from the Lab Guide here, and the repletion approach from the Nutrient Guide here. It is written for discussion with the prescriber and is not a reason to alter therapy.
Mechanistic categories, which recur across the table:
- Absorption: gastric acid suppression (B12 release from food protein, non-heme iron solubility, TRPM6-dependent magnesium uptake), luminal chelation (tetracyclines, fluoroquinolones, bisphosphonates with divalent cations), bile acid sequestration (fat-soluble vitamins), ileal transport inhibition (metformin and the calcium-dependent cubam step).
- Renal loss: loop and thiazide diuretics (magnesium, potassium, thiamine, zinc), SGLT2 inhibitors, cisplatin, aminoglycosides.
- Enzyme inhibition or cofactor antagonism: DHFR (methotrexate, trimethoprim, pyrimethamine), HMG-CoA reductase (CoQ10, dolichol, isoprenoid-dependent K2 synthesis), VKORC1 (warfarin), PLP binding (isoniazid, hydralazine, penicillamine, cycloserine), cobalt oxidation (nitrous oxide).
- Induction of catabolism: CYP-inducing anticonvulsants (vitamin D, folate, vitamin K), glucocorticoids (protein, calcium).
- Consumption: acetaminophen (glutathione), alcohol (thiamine, glutathione, folate), oxidative stressors.
- Microbiome disruption: antibiotics (vitamin K2, biotin, B vitamins, short-chain fatty acids), PPIs (SIBO, which consumes thiamine and B12 and generates propionate).
Acid suppression and gastrointestinal agents
| Drug | Nutrients | Mechanism | Monitoring | Repletion and timing |
|---|---|---|---|---|
| Proton pump inhibitors | B12 (OR about 1.65 for deficiency with over 2 years' use), magnesium (FDA warning 2011; hypomagnesemia refractory to oral repletion in a subset), non-heme iron, zinc, calcium, vitamin C, beta-carotene | Loss of acid-pepsin release of protein-bound B12; TRPM6 requires luminal acidity; Fe(III) insoluble at neutral pH; SIBO secondary to hypochlorhydria | MMA and holoTC annually; RBC magnesium; ferritin and saturation; plasma zinc; consider breath test if bloating | Sublingual hydroxocobalamin and adenosylcobalamin; magnesium glycinate (switching to an H2 blocker often resolves refractory hypomagnesemia); iron by ferritin; zinc with copper; periodic reassessment of indication and deprescribing where appropriate |
| H2 receptor antagonists | B12, iron, zinc (less than PPIs) | Partial acid suppression | MMA, ferritin | As above |
| Antacids | Iron, folate, phosphate (aluminum-containing); magnesium excess (magnesium hydroxide) | Luminal binding and pH | Ferritin with chronic use | Separate minerals by 2 hours |
| Bile acid sequestrants (cholestyramine, colesevelam) | Vitamins A, D, E, K; folate; iron; zinc; magnesium; also bind levothyroxine, digoxin | Sequestration of bile acid micelles | 25-OH-D, PIVKA-II or INR, retinol | Fat-soluble vitamins and other drugs 1 hour before or 4 hours after |
| Orlistat | Vitamins A, D, E, K, beta-carotene | Lipase inhibition | 25-OH-D | Fat-soluble multivitamin at bedtime |
| Laxatives (stimulant, chronic) | Potassium, magnesium, calcium | Secretory loss | Electrolytes | Prescriber review |
Glucose-lowering agents
| Drug | Nutrients | Mechanism | Monitoring | Repletion and timing |
|---|---|---|---|---|
| Metformin | B12 (prevalence of deficiency 6 to 30 percent, dose- and duration-dependent), folate; raises homocysteine; lowers holoTC before serum B12 | Calcium-dependent cubam (IF-B12 receptor) interference; altered ileal motility and bacterial overgrowth | MMA and holoTC at baseline and annually (ADA 2017 guidance supports periodic B12 assessment); homocysteine | Hydroxocobalamin and adenosylcobalamin 1,000 to 2,000 mcg sublingual; calcium supplementation partially reverses the absorption defect; neuropathy attributed to diabetes should prompt MMA |
| SGLT2 inhibitors | Raise serum magnesium; urinary loss of water-soluble vitamins is modest | Osmotic diuresis | RBC magnesium | Usually none |
| Thiazolidinediones | Bone loss (calcium, vitamin D context) | PPAR-gamma shift from osteoblast to adipocyte lineage | Bone density | Vitamin D with K2 |
| Insulin | Intracellular shift of potassium, magnesium, phosphate | Na/K-ATPase activation | RBC magnesium, potassium | Magnesium where low |
Cardiovascular agents
| Drug | Nutrients | Mechanism | Monitoring | Repletion and timing |
|---|---|---|---|---|
| Statins | CoQ10 (plasma falls 16 to 54 percent), vitamin K2 (MK-4 synthesis requires geranylgeranyl-PP from the mevalonate pathway), dolichol, heme A, selenoprotein synthesis (isopentenyl-tRNA); modest vitamin D and omega-3 effects | HMG-CoA reductase inhibition upstream of the farnesyl-PP branch point | CK and symptoms; omega-3 index; CoQ10 level where available | Ubiquinol 100 to 200 mg with a fat-containing meal (RCTs on myalgia are mixed; the biochemical depletion is consistent); K2 MK-7 100 to 200 mcg; SLCO1B1 genotype where myalgia recurs |
| Loop diuretics | Thiamine (urinary loss proportional to diuresis; prevalence of deficiency in heart failure on furosemide reported up to 90 percent in some series), magnesium, potassium, calcium, zinc, pyridoxine | Inhibition of NKCC2 with downstream reduced paracellular reabsorption | Whole-blood TDP or transketolase; RBC magnesium; potassium | Thiamine 100 to 300 mg or benfotiamine (several small trials improve ejection fraction in thiamine-deficient heart failure); magnesium; potassium per prescriber |
| Thiazide and thiazide-like diuretics | Magnesium, potassium, zinc, sodium; raise calcium and uric acid | NCC inhibition; distal magnesium wasting | RBC magnesium, potassium, zinc | Magnesium; zinc with copper |
| ACE inhibitors | Zinc (urinary loss); raise potassium | Zinc-chelating sulfhydryl (captopril) and renal effects | Plasma zinc, potassium | Zinc with copper; no potassium supplementation without prescriber |
| Angiotensin receptor blockers | Raise potassium; minor zinc effect | Potassium | ||
| Beta blockers | CoQ10 (inhibition of CoQ10-dependent enzymes), melatonin (suppressed nocturnal secretion via beta-1 blockade of pineal synthesis) | Receptor-mediated | Sleep quality | Ubiquinol; melatonin 0.5 to 1 mg has RCT support for beta-blocker-associated insomnia |
| Digoxin | Magnesium, thiamine, calcium | Renal loss; hypomagnesemia potentiates toxicity | RBC magnesium | Magnesium repletion is standard |
| Hydralazine | Pyridoxine | Forms a hydrazone with PLP | Plasma PLP | P5P 25 to 50 mg |
| Warfarin | Vitamin K (therapeutic target) | VKORC1 inhibition | INR | Consistent intake; no initiation or cessation of K-containing supplements without prescriber; CYP2C9 and VKORC1 genotype informs dosing |
| Aspirin, chronic | Vitamin C, folate, iron (occult loss) | Mucosal injury; competition for ascorbate uptake | Ferritin | Ascorbate; iron by ferritin |
| Amiodarone | Thyroid (iodine load), vitamin D | Iodine content, CYP effects | Thyroid panel, 25-OH-D | Endocrine monitoring |
Hormonal agents
| Drug | Nutrients | Mechanism | Monitoring | Repletion and timing |
|---|---|---|---|---|
| Combined oral contraceptives | Pyridoxine (altered tryptophan metabolism and PLP binding), folate, B12 (lower serum without clear tissue deficiency), riboflavin, ascorbate, zinc, magnesium, selenium; raise copper, ceruloplasmin, iron, retinol, SHBG, and CRP | Estrogen induction of hepatic proteins and altered renal handling | Plasma PLP, RBC folate, copper and zinc together, homocysteine, hs-CRP | P5P; folinic acid or methylfolate (preconception in particular); magnesium; zinc (copper is already elevated, so the ratio is the target); interpret copper and ceruloplasmin as estrogen-raised |
| Oral estrogen replacement | As above; raises SHBG and copper; transdermal estrogen has less hepatic effect | First-pass hepatic effect | Copper, zinc, SHBG | As above |
| Glucocorticoids (systemic; high-dose inhaled) | Calcium (reduced absorption, increased excretion), vitamin D, potassium, magnesium, zinc, ascorbate, chromium, protein (proteolysis), vitamin K | Reduced intestinal calcium transport, renal loss, catabolism | 25-OH-D, bone density on courses over 3 months, potassium, glucose | Vitamin D with K2 and magnesium; calcium from food; protein 1.2 to 1.6 g/kg; bone protection per guideline |
| Levothyroxine | None depleted; absorption reduced 20 to 40 percent by calcium, iron, soy, coffee, PPIs, sucralfate, bile acid sequestrants | Luminal binding and pH | TSH, free T3 | Empty stomach, 4 hours from iron and calcium, consistent timing; consider liquid or gel formulations with PPIs |
| Spironolactone, eplerenone | Raise potassium; spironolactone may lower zinc | Aldosterone antagonism | Potassium | No potassium supplementation |
| GnRH agonists, aromatase inhibitors | Bone (calcium, vitamin D context) | Estrogen deprivation | Bone density, 25-OH-D | Vitamin D with K2, magnesium, resistance training |
Antimicrobials
| Drug | Nutrients | Mechanism | Monitoring | Repletion and timing |
|---|---|---|---|---|
| Broad-spectrum antibiotics | Vitamin K2 (menaquinone-producing taxa), biotin, folate, B12, riboflavin, short-chain fatty acids | Microbiome depletion | None routinely; INR if anticoagulated | Post-course probiotics (not during, for most strains); K2 and B complex for prolonged courses |
| Tetracyclines | Calcium, magnesium, iron, zinc (bidirectional: drug absorption is also reduced) | Luminal chelation | Minerals 2 to 3 hours apart | |
| Fluoroquinolones | Magnesium, iron, zinc, copper (chelation); mitochondrial injury (mtDNA, ROS); collagen degradation (MMP induction, hydroxylase inhibition) | Chelation of divalent cations; topoisomerase effects on mtDNA; iron chelation inhibiting Fe/2-OG dioxygenases | Tendon symptoms, fatigue, neuropathic symptoms; RBC magnesium | Avoid in connective tissue laxity absent clear indication (FDA boxed warning 2008, expanded 2018); magnesium repletion during and after; NAC and vitamin E plus selenium have preclinical and one small human prevention trial; withhold iron and copper during the acute phase (Fenton chemistry); minerals 2 to 6 hours apart from doses |
| Trimethoprim, trimethoprim-sulfamethoxazole | Folate | Bacterial and (weakly) human DHFR inhibition | RBC folate, CBC with prolonged use | Folinic acid (bypasses DHFR) rather than folic acid |
| Pyrimethamine | Folate | DHFR inhibition | CBC | Folinic acid is standard |
| Isoniazid | Pyridoxine, niacin | PLP hydrazone formation; impaired tryptophan to niacin conversion | Neuropathy | P5P 25 to 50 mg co-prescribed as standard |
| Cycloserine, penicillamine | Pyridoxine | PLP binding | Plasma PLP | P5P |
| Metronidazole | Possible B vitamin effects; dysgeusia | Zinc if dysgeusia persists | ||
| Ketoconazole, high-dose fluconazole | Vitamin D (CYP27B1 inhibition), cortisol and testosterone synthesis | CYP inhibition | 25-OH-D | Vitamin D |
| Aminoglycosides, amphotericin | Magnesium, potassium, calcium | Renal tubular loss | Electrolytes, RBC magnesium | Repletion per prescriber |
Analgesic, psychiatric, and neurologic agents
| Drug | Nutrients | Mechanism | Monitoring | Repletion and timing |
|---|---|---|---|---|
| NSAIDs, chronic | Iron (occult blood loss), folate, ascorbate; mucosal injury raising permeability | COX inhibition, mucosal injury | Ferritin, fecal calprotectin | Iron by ferritin; zinc-carnosine and glutamine for mucosal repair |
| Acetaminophen, regular | Glutathione, cysteine; methionine and glycine conjugation substrates | NAPQI detoxification consumes GSH | GGT, liver enzymes | NAC and glycine; absolute avoidance with alcohol |
| Opioids | Secondary: constipation impairs mineral and conjugate excretion; hypogonadism with chronic use | Mu-receptor effects on motility and the HPG axis | Bowel function, testosterone | Magnesium citrate, fiber; endocrine review |
| SSRIs, SNRIs | Sodium (SIADH, particularly in older adults); folate status predicts response and methylfolate augmentation has RCT support; possible effects on B12 utilization; bone density with long use | Serotonergic effects on ADH | Sodium in older adults; RBC folate | L-methylfolate 7.5 to 15 mg has augmentation data in treatment-resistant depression with low folate; not combined with tryptophan or 5-HTP without oversight |
| Tricyclics | Riboflavin, CoQ10 | Inhibition of riboflavin metabolism | Riboflavin, ubiquinol | |
| Enzyme-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone) | Folate, vitamin D (CYP24A1 induction), vitamin K, biotin, B12, calcium; bone loss | Hepatic enzyme induction, impaired absorption | RBC folate, 25-OH-D, bone density, homocysteine | Folinic acid (folic acid can lower phenytoin levels; folinic acid is the preferred form); vitamin D with K2; biotin |
| Valproate | Carnitine (formation of valproylcarnitine and inhibition of carnitine transport), folate, biotin, vitamin D, zinc, selenium | Carnitine conjugation and OCTN2 inhibition | Plasma free carnitine, acylcarnitine profile, RBC folate, ammonia | L-carnitine 50 to 100 mg/kg (standard for valproate-associated hyperammonemia and recommended prophylactically in several guidelines); folinic acid; biotin |
| Gabapentinoids | Minimal | |||
| Lithium | Raises calcium (parathyroid effect), lowers thyroid function, affects sodium and water handling, may lower folate utilization | Calcium, PTH, thyroid panel, renal function | Prescriber-managed | |
| Antipsychotics | Insulin resistance, dyslipidemia; possible riboflavin and CoQ10 effects | Metabolic receptor effects | Fasting insulin, lipids, A1c | Metabolic monitoring per guideline |
| Nitrous oxide | Cobalamin (irreversible oxidation of cob(I)alamin on methionine synthase) | Cobalt oxidation | MMA and homocysteine after exposure when symptomatic; preoperative B12 status in at-risk patients | Hydroxocobalamin before and after planned anesthesia in marginal patients; recreational use produces subacute combined degeneration |
| Levodopa | Raises homocysteine (COMT methylation of levodopa consumes SAMe); B6, folate, B12 | SAMe consumption | Homocysteine | Folate, B12, B6 (carbidopa limits the historical B6 problem) |
| Methylphenidate, amphetamines | Appetite suppression with secondary intake deficits; zinc and iron status affect response | Ferritin, zinc | Iron and zinc by labs |
Immunologic, rheumatologic, oncologic, and other
| Drug | Nutrients | Mechanism | Monitoring | Repletion and timing |
|---|---|---|---|---|
| Methotrexate | Folate (therapeutic target), B12 utilization; raises homocysteine | DHFR inhibition | RBC folate, CBC, liver enzymes | Folinic acid 5 to 15 mg or folic acid per rheumatology protocol on non-methotrexate days; folinic acid is the rescue form in oncology dosing |
| Sulfasalazine | Folate | Inhibits DHFR and intestinal folate transport | RBC folate | Folinic acid |
| Colchicine | B12 (ileal mucosal effect), beta-carotene | Mucosal toxicity | MMA | B12 |
| Hydroxychloroquine | Minimal | |||
| Bisphosphonates | None depleted; require calcium and vitamin D for efficacy; chelate minerals in the gut | Luminal binding | 25-OH-D | Vitamin D with K2 and magnesium; separate minerals by 30 minutes or more per label |
| Platinum chemotherapy | Magnesium (renal wasting, often persistent), potassium, calcium | Tubular injury | RBC magnesium | Magnesium repletion per oncology |
| 5-fluorouracil, capecitabine | Thiamine (rare Wernicke's), folate pathway | Thiamine utilization | Oncology-directed | |
| Antioxidant supplementation during cytotoxic therapy | Context-dependent | May blunt ROS-dependent cytotoxicity | Oncologist directs; not self-initiated | |
| Ethanol | Thiamine (absorption, phosphorylation, storage), folate, pyridoxine, B12, magnesium, zinc, retinol, ascorbate, selenium, glutathione; raises iron absorption | Multiple: transporter inhibition, hepatic storage, renal loss, GSH consumption, CYP2E1 induction | Whole-blood TDP, RBC folate, RBC magnesium, GGT, ferritin | Thiamine before any glucose load; then folate, magnesium, zinc; reduction of intake is the primary lever |
| Caffeine, high intake | Calcium and magnesium (urinary), iron (tannin binding with meals), modest B vitamin loss | Diuresis, chelation | Separate from iron-containing meals; CYP1A2 slow metabolizers limit afternoon intake | |
| Tobacco and nicotine | Ascorbate (requirement raised by about 35 mg/day), folate, B12, vitamin E, zinc, selenium, beta-carotene (avoid supplemental beta-carotene in smokers: increased lung cancer in two trials) | Oxidative load, altered metabolism | Plasma ascorbate | Ascorbate; cessation |
Interpretive patterns
Stacked depletion. PPI plus metformin plus plant-based diet converges on B12. Thiazide plus PPI plus high caffeine converges on magnesium. Oral contraceptive plus statin plus low-fat diet converges on B6, zinc, and CoQ10 with copper elevated. The combination, not any single agent, is what crosses the threshold.
Attribution error. Metformin-associated neuropathy is frequently B12 deficiency; statin myalgia is in part CoQ10 depletion; PPI-associated fatigue and arrhythmia are frequently magnesium; glucocorticoid myopathy is partly protein and potassium; anticonvulsant bone loss is vitamin D and K. Testing distinguishes drug-induced deficiency from disease progression, and repletion does not require drug discontinuation.
Timing. Levothyroxine, tetracyclines, fluoroquinolones, and bisphosphonates require separation from divalent cations (2 to 4 hours); fat-soluble vitamins require separation from sequestrants and orlistat (4 hours); most other combinations are compatible.
Drug-nutrient interactions in the other direction. Vitamin K with warfarin, potassium with RAAS blockade and potassium-sparing diuretics, folic acid with methotrexate timing, tryptophan and 5-HTP with serotonergic drugs, high-dose niacin with statins (myopathy), St John's wort with CYP3A4 substrates, calcium and iron with levothyroxine, and antioxidants during cytotoxic therapy each require prescriber coordination before any change.
Educational and research content, not medical advice. The author holds a PhD in cellular and molecular nutrition, is not a licensed physician, and does not diagnose, treat, cure, or prevent disease. Medication decisions belong with the prescriber; several agents listed interact with the supplements named beside them and require coordination before any change.
